Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke
- PMID: 18474730
- PMCID: PMC2663573
- DOI: 10.1001/archneur.65.5.575
Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke
Comment on
-
Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke.Arch Neurol. 2008 May;65(5):607-11. doi: 10.1001/archneur.65.5.noc70077. Epub 2008 Mar 10. Arch Neurol. 2008. PMID: 18332238
References
-
- Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–1587. - PubMed
-
- Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105(14):1679–1685. - PubMed
-
- Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–282. - PubMed
-
- Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke: The NINDS t-PA Stroke Study Group. Stroke. 1997;28(11):2109–2118. - PubMed
-
- Uyttenboogaart M, Koch MW, Koopman K, Vroomen PCAJ, De Keyser J, Luijckx G-J. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008;65(5):607–611. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
